Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.41 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | METAP1 | P53582 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | CPN1 | P15169 | 3/20 | 0.39 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.39 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1527354 | 1.00 | CA2 (0.44) | CA2MAPK1CYP2C9CYP2C19HIF1A | |
| SCHEMBL435610 | 0.98 | CYP2C9 (0.45) | CA2MAPK1CYP2C9CYP2C19HIF1A | |
| SCHEMBL1456466 | 0.93 | LCK (0.52) | LCKPPARDZDHHC20ZDHHC2GPR84 | |
| SCHEMBL8734938 | 0.93 | LCK (0.52) | LCKPPARDZDHHC20ZDHHC2GPR84 | |
| SCHEMBL1457152 | 0.93 | LCK (0.52) | LCKPPARDZDHHC20ZDHHC2GPR84 | |
| SCHEMBL8735257 | 0.93 | LCK (0.52) | LCKPPARDZDHHC20ZDHHC2GPR84 | |
| SCHEMBL1032475 | 0.93 | LCK (0.47) | CYP2C9CYP2C19HIF1ALCKPPARD | |
| SCHEMBL3423679 | 0.93 | LCK (0.52) | LCKPPARDZDHHC20ZDHHC2GPR84 | |
| SCHEMBL5375201 | 0.93 | LCK (0.52) | LCKPPARDZDHHC20ZDHHC2GPR84 | |
| SCHEMBL11622995 | 0.93 | LCK (0.52) | LCKPPARDZDHHC20ZDHHC2GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112695214-B | Lanthanum extraction material and preparation method thereof | 江苏南方永磁科技有限公司 | 2022-04-12 | — | — | CN | claimed |
| CN-112695214-A | Lanthanum extraction material and preparation method thereof | 江苏南方永磁科技有限公司 | 2021-04-23 | — | — | CN | claimed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | claimed |
| US-20170101440-A1 | METHODS OF TREATING OPHTHALMIC DISEASES USING NPR-B AGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-04-13 | — | — | US | claimed |
| EP-3110427-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | Urigen Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | claimed |
| WO-2015127416-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | URIGEN PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | WO | claimed |
| CN-101020761-B | Ether-ester plasticizers | FERRO CORP | 2011-07-13 | — | — | CN | claimed |
| CN-101020761-A | Ether-ester plasticizers | FERRO CORP (US) | 2007-08-22 | — | — | CN | claimed |
| US-20070123622-A1 | ETHER-ESTER PLASTICIZERS | FERRO CORPORATION (US) | 2007-05-31 | — | — | US | claimed |
| WO-2006105842-A1 | SYNERGISTS FOR BOOSTING THE ACTION OF REPELLENTS | MERCK PATENT GMBH (DE) | 2006-10-12 | — | — | WO | claimed |
| EP-1456322-A4 | GLYCERIN TRIESTER PLASTICIZER | FERRO CORP (US) | 2005-03-16 | — | — | EP | claimed |
| EP-1456322-A1 | GLYCERIN TRIESTER PLASTICIZER | FERRO CORPORATION (US) | 2004-09-15 | — | — | EP | claimed |
| US-6740254-B2 | PHTHALATE-FREE PLASTICIZER INCLUDES A MIXTURE TRIESTERS OF GLYCERIN, ATLEAST TWO SELECTED FROM GYCERYL(1,2)BIBUTANOATE BENZOATE, GLYCERYL(1,3)BISBUTANOATE BENZOATE, GLYCERYL(1,2 OR 1,3)BISBENZOATE BUTANOATES | FERRO CORPORATION | 2004-05-25 | — | — | US | claimed |
| WO-2003054106-A1 | GLYCERIN TRIESTER PLASTICIZER | FERRO CORPORATION (US) | 2003-07-03 | — | — | WO | claimed |
| US-20030116750-A1 | Glycerin triester plasticizer | POLYMER ADDITIVES, INC. | 2003-06-26 | — | — | US | claimed |
| US-20030120104-A1 | Glycerin triester plasticizer | FERRO CORPORATION (US) | 2003-06-26 | — | — | US | claimed |
| US-6221367-B1 | EXPOSING A BIOLOGICALLY ACTIVE AGENT TO A COMPLEXING PERTURBANT TO REVERSIBLY TRANSFORM THE BIOLOGICALLY ACTIVE AGENT TO THE INTERMEDIATE STATE AND TO FORM A TRANSPORTABLE SUPRAMOLECULAR COMPLEX | EMISPHERE TECHNOLOGIES, INC. | 2001-04-24 | — | — | US | claimed |
| US-6071538-A | TRANSPORTATION ACROSS CELL MEMBRANE OR LIPID BILAYER | EMISPHERE TECHNOLOGIES, INC. (US) | 2000-06-06 | — | — | US | claimed |
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | disclosed |
| WO-1995028920-A1 | ACIDS AND ACID SALTS AND THEIR USE IN DELIVERY SYSTEMS | EMISPHERE TECHNOLOGIES, INC. (US) | 1995-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | SI, SLC20A1, SLC20A2 | CA2 1717/4885MAPK1 3137/4885CYP2C9 512/4885 |
| US-20170101440-A1 | METHODS OF TREATING OPHTHALMIC DISEASES USING NPR-B AGONISTS | NPR1, EDNRB, NPR3 | CA2 2387/4885MAPK1 1766/4885CYP2C9 4672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.